CVS
CVS HEALTH CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Days claims payable | 42.9 | As of March 31, 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVS
this stock
CVS HEALTH Corp
|
$132.89B | +32.3% | +10.9% | 45.7 | 1.6% |
|
UNH
Unitedhealth Group Inc
|
$385.62B | +29.6% | +11.8% | 32.0 | 2.0% |
|
ELV
Elevance Health, Inc.
|
$90.39B | +19.5% | +9.4% | 17.6 | 2.8% |
|
CI
Cigna Group
|
$77.63B | +7.2% | +11.2% | 12.4 | 2.4% |
|
HUM
Humana Inc
|
$47.17B | +53.9% | +10.1% | 41.9 | 3.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVS | -0.5% | +6.3% | +29.1% | +0.7% | +32.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -1.9% | +2.2% | +20.0% | -0.4% | +21.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.